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Abstract
We developed an efficient, automated 2-step purification protocol for the production of milli-
gram quantities of untagged recombinant rat lactate dehydrogenase A (rLDHA) from E. coli,
using the ÄKTAxpress™ chromatography system. Cation exchange followed by size exclu-
sion results in average final purity in excess of 93% and yields ~ 14 milligrams per 50 ml of
original cell culture in EnPresso B media, in under 8 hrs, including all primary sample pro-
cessing and column equilibration steps. The protein is highly active and coherent biophysi-
cally and a viable alternative to the more problematic human homolog for structural and
ligand-binding studies; an apo structure of untagged rLDHA was solved to a resolution 2.29
Å (PDB ID 5ES3). Our automated methodology uses generic commercially available pre-
packed columns and simple buffers, and represents a robust standard method for the pro-
duction of milligram amounts of untagged rLDHA, facilitating a novel fragment screening
approach for new inhibitors.
Introduction
As the breadth and pace of large biomedical, drug discovery and structural genomics programs
has increased, the requirement for protein production strategies to be reliable and robust has
become more and more critical. The need to regularly generate milligrams of highly pure,
biophysical coherent and active protein, with little batch variation has resulted in modern chro-
matography instruments becoming increasingly automated [1–4], separation media and
expression/production technologies becoming increasingly sophisticated and routinely imple-
mented outside of specialist protein production labs, and effective preparative protein purifica-
tion becoming more routine [5–12]. Most methodologies tend to be protein/protein-family
specific, utilising specific differences in biophysical properties particular to the individual pro-
tein(s), making them hard to translate efficiently into generic or high-throughput purification
strategies. Coupled to this is the fact that the majority of purification strategies are multistep
[13–18]) and most lab-scale chromatography instrumentation normally handles only a single
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step at a time, and thus can involve significant user intervention and time-consuming manual
processing. High-end conventional LC systems can be adapted to run automated multi-step
protocols, either by adaptive software/hardware additions [19] or by intelligent peak collection
and sample diversion/loading strategies using the existing hardware [20]. However, this auto-
mation/parallelization is less than straightforward for non-experts to “standardise”. There are
often significant operational differences between how different labs use them (delay volumes,
tubing diameters, valve configurations, column types etc.) that make this adaptive automated
method development harder to routinely implement.
The ÄKTAxpress™ liquid chromatography system (GE Healthcare) was the first commer-
cially available standardised lab-scale system designed specifically to run automated, paralle-
lized, multi-step (up-to 4) purification protocols [3, 21, 22]. The non-modular design, with
identical flow path delay volumes, gradient delay volumes, pre-defined commercially standard-
ised column types and the same sets of limited user-editable protocol design parameters,
means in theory, that there is no appreciable difference in way the instruments are run between
laboratories. The vast bulk of ÄKTAxpress™ protocols utilize affinity chromatography as the
first step [3, 23], as enrichment best fits the sample handling restrictions for subsequent proto-
col steps. However, affinity tags, and optimizing their subsequent removal (regularly pertinent
for structural analysis), occasionally causes as many problems as the development of the purifi-
cation protocol itself (this is even the case for the simple poly-histidine tag [21, 22, 24]). To our
knowledge, only a handful of generic protocols have been published for the purification of
untagged proteins using such automated systems [21].
One protein of particular interest to us as a potential therapeutic anti cancer target is mam-
malian lactate dehydrogenase A (LDHA). For decades, it has been known that certain tumors
alter the metabolism of the transformed cells they are in; the so-called Warburg effect [25, 26].
Many tumor-transformed tissues have severely altered glucose metabolism and greatly increase
the rate of glucose uptake, relative to normal cells, and metabolise this via glycolysis and not by
mitochondrial oxidative phosphorylation [27–36]. In contrast to normal tissues, such glyco-
lytic glucose depletion occurs in cancer cells even in abundant oxygen levels [27]. Warburg’s
“aerobic glycolysis” [25, 26] is an attractive model marker that distinguishes between tumors
and healthy tissues, and one potentially exploitable for development of new anti-cancer agents
[28, 37–43]. LDHA (also known as LDH-M and LDH-5) is a homotetrameric enzyme that cat-
alyzes the cytosolic conversion of pyruvate to lactate in the final step of glycolysis, oxidizing
nicotinamide adenine dinucleotide (NADH) in the process [37]. Elevated LDHA levels are
integrally associated with many cancer types and it appears likely to be a principal factor in the
altered metabolisms required for the growth and proliferation of certain tumors [27–29, 37, 39,
44, 45]. These observations have highlighted LDHA as an attractive target for new anti-cancer
agents for use against glycolytic tumors [38, 39].
We found that the human LDHA protein was more problematic to work with than the rat
homologue (despite structures being available, PDB code 1i10 [46]), similar to the observations
of other labs [38, 39]. In our hands the presence of his-tags, especially at the N-terminus,
adversely affected the levels of soluble expression, protein activity, tag-cleavage and hampered
the subsequent ability to generate a robust protein crystal structure rationale for our small mol-
ecule/fragment inhibitor studies. It is unclear why this should be the case, but on average the
levels of soluble expression and activity of the tagged protein were ~ 15–18% less than the
untagged. Partial removal of the tag–at best 50% efficient–is very likely explained by occlusion
of the N-terminus and protease site in quaternary structure of the LDHA. This material did
not yield crystals.” Considering extremely high sequence identity between the human and rat
LDHA sequences (94% identity), the fact that the cofactor and substrate binding sites are iden-
tical, and recent structural work from the literature with the rat homologue [38, 39], we
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developed a very efficient, automated purification protocol for the production of milligram quan-
tities of very pure, untagged rat LDHA (rLDHA), as an alternative to the human protein, from E.
coli, using the ÄKTAxpress™ chromatography system. The 2-step protocol (cation exchange and
size exclusion) results in a typical final purity of 93% and final yield of ~ 14 mg per 50 ml of
original cell culture in EnPresso B media, in under 8 hrs. The protein is highly active and biophy-
sically coherent, and allowed us to develop a novel rationale for generation of a soakable protein
crystal system (a structure of rLDHAwas solved to 2.29 Å resolution; PDB ID 5ES3). The auto-
mated protocol uses standard commercially available pre-packed columns and simple buffers
and represents a robust generic method for the automated production of untagged rLDHA.
Materials and Methods
Materials
All chemicals used were of the highest grade available commercially.
Plasmid construction
The codon optimsed (Geneart) ORF corresponding to amino acids 1–332 of full-length wild
type rat lactate dehydrogenase A (rLDHA) was first cloned into pDONR-221 (Invitrogen) and
subsequently sub-cloned into pDEST-14 (Invitrogen) using standard GATEWAYmethodol-
ogy and the final vector sequence verified.
Protein Expression and Purification
Over-expression of rLDHA was achieved by addition of IPTG to 1 mM to OverExpress C41
BL21(DE3) E. coli (Lucigen), transformed with the rLDHA expression plasmid, grown shaking
(260 rpm) at 30°C for 24 hrs in 50 ml of EnPresso B media (BioSilta™) in a 500 ml flask. In our
laboratory this strain of E. coli (a phenotypic mutant selected for conferring tolerance to toxic
proteins) consistently performs better, in terms of soluble expression, than standard BL21
(DE3) strains with both non-toxic and toxic proteins. Cells were harvested by centrifugation at
4,000 x g for 10 min at 4°C and cell pellets used immediately or flash frozen in liquid nitrogen
and stored at -70°C.
All purification was performed on ÄKTAxpress™ (GE Healthcare) equipment at 6°C. The
ÄKTAxpress™ instruments were used in a standard cold-run configuration and 10 ml collec-
tion loops, with modifications described below. The cell pellet from 50 ml of EnPresso B cul-
ture was re-suspended in Buffer-A (100 mMNaOAc, pH 5.0; 50 mM NaCl) to 10% weight per
volume, supplemented with 1 protease inhibitor tablet (cOmplete™, EDTA-free, Roche). Lysis
was performed at 6°C by a single passage through a Constant Systems Cell Disruptor TS Series
Benchtop instrument (Constant Systems) set to 25 kPsi, and cellular debris removed by centri-
fugation at 50,000 × g for 45 min at 4°C. Following lysis, the clarified supernatant was applied
to an ÄKTAXpress™ system fitted with 5 ml HiTrap SP HP ion-exchange (IEX) and HiLoad
26/60 Superdex-200pg size exclusion (SEC) columns (GE Healthcare), attached to the system
with the default system lengths of 1.0 mm i.d. Tefzel1 tubing. Flow rates were 5 ml.min-1 and
3.2 ml.min-1, IEX and SEC steps, respectively. Proteins were detected by absorbance at 280 nm.
Following sample loading, unbound material was washed through the IEX matrix with a fur-
ther 25 column volumes of Buffer-A. Elution from the IEX matrix was performed by a 10 col-
umn volume linear gradient from 0–100% Buffer-B (100 mMNaOAc, pH 5.0; 1 M NaCl),
with default peak collection parameters for level and slope, collecting 10 ml into a single loop;
rLDHA invariably eluted between 18% - 46% Buffer-B. The contents of the IEX loop were
loaded onto the SEC column with a peak-injection-flush-volume of 13 ml, and eluted in Buffer-
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C (100 mMHEPES pH 7.5; 150 mMNaCl), with peak collection set to start after 0.26 column
volumes, collecting 2 ml fractions throughout with peak collection default parameters for
level and slope. Invariably, fractions E3 –F12 of the rLDHA peak were pooled, concentrated to
~ 1 mg.ml-1 and stored at 4°C on ice. rLDHA was routinely in excess of 93% pure as judged by
densitometric analysis of SDS-polyacrylamide gels (Fig 1A) and verified as full length protein
by mass spectrometry. An average of 14 mg final yield was routinely obtained from 50 ml of
EnPresso B culture media.
Mono-dispersity and size analysis
Size-exclusion chromatography multi-angled light scattering (SEC-MALS) of rLDH protein.
Size-exclusion chromatography (ÄKTA-Micro; GE Healthcare) coupled to UV, static light
scattering and refractive index detection (Viscotec SEC-MALS 20 and Viscotek RI Detector
VE3580; Malvern Instruments) were used to determine the molecular mass of rLDH in solu-
tion. Multiple injections of 100 μL of 1 mg.ml-1 rLDHA were run on a Superdex-200 10/300
GL (GE Healthcare) size exclusion column pre-equilibrated in Buffer-C at 22°C with a flow
rate of 0.5 ml.min-1. Light scattering, refractive index (RI) and A280nm were analysed by a
homo-polymer model (OmniSEC software, v5.02; Malvern Instruments) using the following
parameters for rLDH protein: @A / @c at 280nm 1.19 AU.ml.mg-1, @n / @c of 0.185 ml.g-1 and
buffer RI value of 1.334. Mass distribution analysis of rLDHA protein sample by dynamic light
scattering (DLS) (data not shown) was performed on a Zetasizer APS (Malvern) with 5 repeat
runs of 60 μl (0.5 mg.ml-1) in Buffer-C at 25°C, with a 120 s equilibration.
rLDHA enzymatic assay
Reaction velocity was determined by measuring the decrease in the absorbance at 340 nm
resulting from the oxidation of NADH [47]. 1 unit of enzymatic activity is defined as the reduc-
tion of 1 μmol of pyruvate per mg per minute, pH 7.5 at 30°C. Reactions were performed with
0.008–0.02 μg of rLDHA at 30°C in Buffer-C supplemented with 300 μMNADH in a total vol-
ume of 3 ml on a Jasco V-550 spectrophotometer. ΔA340/min values were converted to μmol.
min-1.mg-1 using the extinction coefficient of 6,220 M-1.cm-1 for NADH. The initial reaction
rates, Vo (in μmol.min
-1.mg-1), were plotted against the concentration of pyruvate and the data
least squares fit to Eq 1 using Kaleidagraph v4.1.3 software (Synergy Software, reading, PA);
Vo ¼ ðkcat  ½rLDHAÞ  ½Pyruvateo  ð½Pyruvateo=KmÞ ð1Þ
where [rLDHA] is the concentration of rLDHA, [Pyruvate]o is the initial concentration of
pyruvate, kcat is the turnover number and Km is the Michealis constant.
Surface plasmon resonance (SPR)
SPR measurements were performed on a BIAcore T200 instrument (GE Healthcare). SA sensor
chips were purchased from GE Healthcare. rLDHA was biotinylated using EZ-Link™ Sulfo-
NHS-Biotin (Thermo Scientific) in Buffer-C, supplemented with 0.05% surfactant P20. Bioti-
nylated rLDHA was then captured to the desired levels of by varying contact time with the sen-
sor surface, at 30 μl.min-1 in Buffer-C, supplemented with 0.05% surfactant P20. SPR binding
experiments with NADH were performed, in triplicate, at 25°C. A serial dilution concentration
series of NADH ranging from 90 μM– 0.14 μM in Buffer-C, supplemented with 0.05% surfac-
tant P20, was injected over the sensor surface, at 30 μl.min-1 with 30 s association and dissocia-
tion times. The apparent on- and off-rate constants (k+, k-) and the equilibrium dissociation
constant (Kd) were determined by globally fitting a 1:1 kinetic binding model, with mass
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Fig 1. Automated Purification of untagged rLDHA. (A) SDS polyacrylamide gel (4–20% gradient) illustrating the typical level of soluble rLDHA extracted in
the clarified lysate and final purified sample, from OverExpress C41 BL21(DE3) E. coli. S/N, clarified supernatant; Final; final pooled sample. 5 μg total load in
each lane. (B) Typical chromatogram for the automated 2-step purification of rLDH using ÄKTAXpress™. The pre-packed columns used are illustrated above
the corresponding section of the chromatogram; IEX—ion-exchange, GF—gel filtration. Solid black; A280nm in mAU (left axis). Solid red; NaCl gradient in %
Buffer-B (right axis). The inset details the region of the gel filtration column elution from which fractions were collected. Indicated fractions E3 –F12 were
Automated Purification of Untagged Rat Lactate Dehydrogenase A.
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transport considerations, to three different density surfaces (3,122 RU, 5,272 RU & 7810 RU)
simultaneously, using the analysis software (v1.02, GE Healthcare) supplied with the
instrument.
Crystallisation and X-ray structure determination
LDH was concentrated to 22 mg.mL-1 and crystallised using the Morpheus1HT-96 crystalli-
sation screen. Sitting drops were set up using the Douglas Instruments Oryx8 robot to pipette
on to MRC 2 well crystallization plates (Swissci). The protein was mixed with the well solution
(50 μL) in a 1:1 ratio (1 μL drop volume) and incubated at 18°C after plate sealing. A single
crystal appeared in condition G10 (0.1 M Tris/Bicine pH 8.5, 20% ethylene glycol, 10% PEG
8000, 0.02 M of each of sodium formate, ammonium acetate, tri-sodium citrate, sodium/potas-
sium tartrate and sodium oxamate) after a week. Data were collected at Diamond Light Source,
UK, from a single crystal on beamline IO4 at 100 K and were processed using XIA2 [48] utiliz-
ing XDS [49] The structure was solved by molecular replacement using Phaser [50] in the PHE-
NIX suite [51] utilising a single chain from PDB ID 4AJE as the search model. Model building
and initial refinment was carried out using the AutoBuild command in PHENIX, and and miss-
ing loops were fitted using the Fit Loop command. The structure was subjected to several
rounds of refinement in PHENIX and manual refinement in Coot [52], including ligand fitting
and loop re-modelling. Protein structure has the PDB ID 5ES3.
Miscellaneous
SDS-PAGE was performed essentially as described [53]. The molecular mass of rLDHA is
36,400 Da. Protein concentration was determined by measurement of absorbance at 280 nm
and calculated using the extinction coefficient 43,600 M-1.cm-1.
Results and Discussion
We established a streamlined expression and automated 2-step methodology for the produc-
tion of 10s of mg levels of very pure (typically in excess of 93%), highly biophysically coherent
and active mammalian lactate dehydrogenase A (rat LDHA) from E.coli. (Fig 1). From exten-
sive screens, we generated a robust and easily scalable set of conditions for high-level soluble
expression of rLDHA for lab-scale production. Full-length codon optimised rLDHA in
pooled. (C) Mono-dispersity and size analysis. Size-exclusion chromatography multi-angled light scattering (SECMALS) of rLDH protein. Size-exclusion
chromatography (ÅKTA-Micro; GE Healthcare) coupled to UV, static light scattering and refractive index detection (Viscotec SEC-MALS 20 and Viscotek RI
Detector:VE3580; Malvern Instruments) were used to determine the molecular mass of rLDH in solution. 100 μL of 1 mg.mL-1 rLDH was run on a Superdex-
200 10/300 GL (GE Healthcare) size exclusion column pre-equilibrated in Buffer-C, at 22°C with a flow rate of 0.5 mL.min-1. Light scattering, refractive index
(RI) and A280nm were analysed by a homo-polymer model (OmniSEC software, v 5.1; Malvern Instruments) using the following parameters for rLDH protein:
@A / @c at 280nm 1.19 AU.mL.mg-1 and @n / @c of 0.185 mL.g-1. rLDH protein elutes a single sharp peak with apparent molecular mass of ~ 117 ± 15 kDa. and
an Rs of 4.9 ± 0.2 nm (mean ± SD, n = 3). Elution position for standards are shown above the chromatograph. The molecular mass average across the elution
profile is 141.4 kDa. with excellent mono-dispersity (Mw/Mn = 1.001). The theoretical molecular weight of tetrameric rLDH is 145.6 kDa. (monomer = 36.4
kDa.) Protein concentration was determined by measurement of absorbance at 280 nm and calculated using the extinction coefficient of 43,600 M-1.cm-1. (D)
Specific activity of rLHDA verified by oxidation of NADH as function of pyruvate concentration. Assay performed at 30°C in Buffer-C supplemented with 3 mM
NADHmonitoring at 340 nm with 0.01 μg of rLDHA. Km value (fit to Eq 1; solid line) is 0.53 ± 0.08 mM for pyruvate and specific activity is 310 μmol.mg
-1.min-1.
(E) Characterisation of the interaction of NADH with rLDHA using BIAcore T200. Active rLDHA surfaces were generated by capture of biotinylated protein on
SA sensor surfaces (GE Healthcare). Between 3,900 RU– 7800 RU were immobilized on three separate surfaces on a SA sensor chip. Left Panel.
Representative reference corrected SPR binding curves (black), monitored on a surface of 5,272 RU of rLDHA for various dilution series (in the 90 μM–
0.7 μM range) of NADH at 25°C in Buffer-C, supplemented with 0.05% surfactant P20. The apparent on- and off-rate constants (above) were determined by
globally fitting (red) a 1:1 kinetic binding model, with mass transport considerations, to three different density surfaces (3,122 RU, 5,272 RU & 7810 RU)
simultaneously, using the analysis software (v1.02, GE Healthcare) supplied with the instrument. The 1.125 μM sensorgram shows two replicate runs. Mean
values (n = 3, ± SD) determined for the on-rate (k+), off-rate (k-) and equilibrium dissociation constants (Kd) are 0.38 ± 0.06 μM
-1.s-1, 2.7 ± 0.6 s-1 and
7 ± 0.6 μM, respectively. Right Panel. Steady-state affinity determination for NADH binding to rLDHA, fit using a 1:1 Langmuir interaction model (solid red
line), gives a mean Kd value of 6.4 ± 0.3 μM.
doi:10.1371/journal.pone.0146164.g001
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pDEST-14, transformed into OverExpress C41 BL21(DE3) E. coli and cultured in 50 mls of
EnPresso B media, shaking at 260 rpm in 500 ml Erlenmeyer flasks, with 24 hr induction at
30°C by addition of IPTG to 1 mM, typically yields in excess of 20 mg per litre equivalent in
the soluble extract (Table 1; Fig 1A). Culture in 50 ml EnPresso B media produces very high-
density growth and results in biomass generation equivalent to that from 1 litre of traditional
LB media grown under similar conditions. This reduced volume results in considerably easier
and less time-consuming down-stream processing, in terms of centrifugation of the culture,
lysis and clarification and the subsequent sample manipulation for chromatography. A further
advantage of these optimized expression conditions is that scale-up production is substantially
easier to implement than for traditional liquid media. Biomass production from 10 x 100 ml
EnPresso B media cultures (in 1 litre Erlenmeyer shaker flasks grown under the above condi-
tions) is equivalent to 10 litres of fermentation in LB media (300°C for 24 hrs). However, on
average the soluble protein yield is 3 times greater, using our optimized conditions, than that
obtained from 10 L of fermentation in LB media.
We optimised a purification rationale to allow use of standard commercially available pre-
packed columns and simple buffers (See Table 1) and translated it onto ÄKTAXpress™ system
(GE Healthcare) fitted with 5 ml HiTrap SP HP IEX and HiLoad 26/60 Superdex-200pg SEC
columns (GE Healthcare). Lysis and binding in Buffer-A (100 mMNaOAc, pH 5.0; 50 mM
NaCl) allowed effective adsorption on the SP matrix, efficient removal and partitioning of
essentially all of the contaminants and unbound material, and facilitated early elution of
rLHDA during the gradient. Elution from the IEX matrix was performed by a 10 column vol-
ume linear gradient from 0–100% Buffer-B (100 mMNaOAc, pH 5.0; 1 mM NaCl), with
default peak collection parameters for level and slope, collecting 10 ml into a single loop.
rLDHA invariably eluted between 18% - 46% Buffer-B (Fig 1B). We found the minor loss of
material arising from using the entire loop volume was more than compensated by the
increased yield that resulted from collecting 10 ml of sample through the core of the eluted pro-
tein peak for the IEX column (similar to other work from our lab [21]). The contents of the
IEX loop were loaded onto the SEC column with a peak-injection-flush-volume of 13 ml, and
eluted in Buffer-C (100 mMHEPES pH 7.5; 150 mMNaCl), with peak collection set to start
after 0.26 column volumes, collecting 2 ml fractions throughout with peak collection default
parameters for level and slope. The GF elution profile shows a single major peak, eluting at
186 ± 2 ml, with good peak symmetry. Invariably, fractions E3 –F12 of the rLDHA peak were
pooled (Fig 1B, inset), concentrated to ~ 1 mg.ml-1 and stored at 4°C on ice. rLDHA was veri-
fied as full length protein by mass spec. The methodology is very reproducible and results in a
typical final purity of 93% and final yield of ~ 14 mg from 50 ml of original cell culture in
EnPresso B media, in under 8 hrs (Table 1), with minimal manual processing.
Table 1. Automated purification of rLDHA.
Fraction Total protein (mg)a Purity (%)b
Soluble clariﬁed lysate supernatant 248 ~ 13
Pooled HiLoad Superdex200pg 26/60 fractions. 14  93
Fractionation was performed on cell pellets obtained from E. coli cultured in 50 ml of EnPresso B media,
which generates the equivalent biomass of 1 L of traditional liquid LB media.
a Mean values from at least 2 individual repeat runs. Protein concentration in the supernatant and the
pooled fractions was determined by A280 measurements.
b average % purity determined by densitometry of appropriate lanes on reducing SDS-polyacrylamide gels
(4–20% gradient, see Fig 1A).
doi:10.1371/journal.pone.0146164.t001
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Given the relative purity and amount of the material eluting from the IEX column, a 5 ml
resin bed is apt to be able to cope with 4–5 times the initial starting material before dynamic
breakthrough of rLDHA. This would potentially give final yields of 50–60 mgs of rLDHA pro-
tein, but without refinement of the long-term storage conditions, production of this amount of
protein should be cautioned. Storage on ice at 4°C gave little evidence of loss of activity, aggre-
gation or degradation in general for at least 3–4 weeks. After this, a slow loss of activity was
observed. We found that rLDHA to be cold labile at lower temperatures and the protein did
not cope particularly well with freezing (at either -20°C or -80°C) even in the presence of cyro-
protectant (up to 20% glycerol and/or 20% PEG 3000) and at various concentrations ranging
from 0.5–5 mg.ml-1. Variable loss of material and activity (20–70% for both) resulted from
such conditions. Storage as an ammonium sulfate suspension (Buffer-C supplemented with
(NH4)2SO4 to 3.2 M) works well for at least 8 weeks, but there are issues with reliable recovery
of equal amounts of protein from the precipitate, even though specific activity and yield recov-
ery were good; in excess of 85% typically. Nevertheless, the production and purification proto-
col we have developed allows for the rapid and reproducible production of 10s of milligrams of
highly pure rLDHA and somewhat alleviates the long-term storage issues.
Before embarking on a series of crystallisation trials, we next extensively assessed the biophys-
ical coherency and specific activity of the protein product purified by this method. Size-exclusion
chromatography multi-angled light scattering (SEC-MALS) analysis was used to determine the
molecular mass of rLDHA in solution. On a Superdex-200 10/300 GL (GE Healthcare) size
exclusion column, rLDHA protein elutes a single sharp peak with apparent molecular mass of
~ 117 ± 15 kDa. and an Rs of 4.9 ± 0.2 nm (mean ± SD, n = 3). The molecular mass average
across the elution profile is 141.4 ± 3.7 kDa. with excellent mono-dispersity (Mw/Mn = 1.001)
(Fig 1C). This is in excellent agreement with theoretical molecular weight of 145.6 kDa. for tetra-
meric rLDHA (monomer = 36.4 kDa.). Mass distribution analysis was also carried out using
dynamic light scattering (DLS) (data not shown). This further illustrated the very high mono-dis-
persity for the purified protein. Mean modal hydrodynamic radius (Rh) was 4.3 ± 0.17 nm, with
correlative molecular mass of 123 kDa. Hydropro [54] calculations using the 4AJ1.pdb crystal
structure of tetrameric rat LDHA gave an Rh of 4.2 nm with an Rhmax of 4.98 nm. All of these
data illustrate the very high quality of the purified protein and the robustness of the methodology
for the production of very pure, mono-disperse, tetrameric rLDHA.
The purified protein also shows high specific activity. Typical results from enzyme assays
following the oxidation of NADH as function of pyruvate concentration at 30°C are shown in
Fig 1D. Mean Km values for pyruvate were 0.53 ± 0.08 mM the mean specific activity was
310 ± 30 units.mg-1.min-1. These values are in good agreement with the literature for mamma-
lian LDHA isoforms with Km values for pyruvate which ranging from 0.05 to 1 mM and spe-
cific activity ranging from 50–600 units.mg-1.min-1 [39, 47]. The interaction of the co-factor
NADH was also analyzed using SPR on a BIAcore T200 (Fig 1E). Specific activity of immobi-
lized biotinylated rLDHA was again very high; typically in excess of 85%. Representative refer-
ence corrected SPR binding curves (black), for NADH binding to immobilised rLHDA are
shown in Fig 1E (left panel). The mean apparent on-rate (k+), off-rate (k-) and equilibrium dis-
sociation constants (Kd), determined by globally fitting (red) a 1:1 kinetic binding model, with
mass transport considerations, were 0.38 ± 0.06 μM-1.s-1, 2.7 ± 0.6 s-1 and 7 ± 0.6 μM, respec-
tively. Steady-state affinity determination for NADH binding to rLDHA, gives a mean Kd value
of 6.4 ± 0.3 μM. All of these kinetic and steady state values are in excellent agreement with the
literature [39, 47].
We next embarked on development of a robust protein crystallisation rationale for use in
soaking and co-crystallisation of fragments and small molecules for development of inhibitors
for LDHA. Crystals grew using the commercially available Morpheus1 screen with diffracting
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crystals appearing where oxamate (a known inhibitor of LDH [55] was present as an additive.
The structure (PDB ID 5ES3) was solved to a resolution of 2.29 Å (Table 2) with the asymmet-
ric unit containing 2 complete tetramers (Fig 2A). Upon close inspection both tetramers
appeared in a ‘fully open’ conformation (all subunits in the tetramer adopting an open confor-
mation with respect to the active site loop) despite the presence of electron density in the lac-
tate binding site. The electron density was attributed to the presence of oxamate in the
crystallization conditions. Oxamate was therefore modelled in to the density present in each of
the 8 subunits in the assymetric unit (Fig 2B). Of note, to our knowledge this is the first exam-
ple of an LDH crystal structure where oxamate (or lactate or oxalate) is bound without the
presence of a co-factor (NAD/NADH) or co-factor mimic. Moreover, with the exception
PDBID 1A5Z (Thermotoga maritima LDH [56]) our structure is also the first to have oxamate
bound yet still be in a ‘fully open’ conformation. This conformation is depicted in Fig 2C where
chain A from our structure is overlaid with another Rat LDH (PDBID 4AJ1) where malonate is
bound in the presence of an NAD-mimic [38]. In the T.maritima structure, the open confor-
mation is caused by a Cd2+ ion binding in the active site and stopping the loop from closing.
These conformational state changes are important to charcaterise as they present very different
molecular contacts surfaces for the binding of small molecules and fragments.
We have developed reliable and robust automated protocols, for the production and purifi-
cation of 10s of milligram amounts of very pure, highly active and biophysically coherent
untagged recombinant rat lactate dehydrogenase using the ÄKTAxpress™ liquid chromatogra-
phy system. The automated 2-step protocol uses generic commercially available pre-packed
columns and minimal buffers and has minimal user input. A novel protein crystallisation ratio-
nale was developed for fragments and small molecule.
Table 2. Crystallographic data.
LDH:oxamate
data collection
resolution (Å) 2.29
space group P212121
unit cell (Å)
a 84.1
b 146.6
c 284.9
unique reﬂectionsa 158361 (11483)
completeness (%)a 100 (99)
Rmerge (%)
a 12.7 (70.2)
I/σa 11.9 (2.7)
reﬁnement
R (%) 17.0
Rfree (%) 20.3
all atoms used in reﬁnement 21652
water 1321
Validationb (% of all residues)
favoured 98.0
allowed 100.0
disallowed 0.0
aValues in parentheses refer to the highest-resolution shell.
bValidation was performed using MolProbity. PDB ID 5ES3
doi:10.1371/journal.pone.0146164.t002
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hand panel) (PDB ID 5ES3). (B) Lactate binding site of rLDH with oxamate bound. Density contoured at 1σ. (C) Single subunit overlay of oxamate-bound
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